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DETECTION OF SILENT MYOCARDIAL ISCHEMIA IN CHILDREN
WITH FAMILIAL HYPERLIPIDEMIA BY GATED MYOCARDIAL
PERFUSION SCINTIGRAPHY
Pinar Kiratli1, Meltem Tuncali1, S. Ozkutlu2
1Nuclear Medicine, Hacettepe University Medical Faculty, Ankara, Turkey
2Pediatrics, Hacettepe University Medical Faculty, Ankara, Turkey
Aim: Familial hyperlipidemia (FHL) is a genetic disease characterized elevated serum
levels of total cholesterol and low-density lipoprotein (LDL) which results in
a markedly increased incidence of atherosclerosis and coronary artery disease in ho-
mozygotes. These changes are seen to a lesser extent in dyslipidemic pediatric pa-
tients as well. The purpose of this study was to detect silent myocardial ischemia with
Tc-99m MIBI stress gated single-photon emission computed tomography myocardial
perfusion scintigraphy (MPS) in patients with FHL and correlate the scan results with
clinical variables.
Material and methods: Six asymptomatic dyslipidemic (8 to 17 years) and 13 homozy-
gotes FHL (7 to 17 years) patients were evaluated with clinical assessment, blood lipid
measurement and stress gated MPS.
Results: Five homozygotes FHL patients had abnormal MPS. Ischemia was present in
4 patients and one child had myocardial wall dyskinesia. The coronary angiography of
5 homozygote patients who had an abnormal MPS demonstrated > 50% stenosis in
their coronary arteries. Cardiac surgery was then performed in 4 and aggressive repet-
itive plasma exchange was instituted in 1 patient. The MPS of 6 dislipidemic patients
were normal. The mean ± SD values of total cholesterol and LDL levels in homozygotes
with abnormal scans were 626 ± 55 mg/dl and 576 ± 55, respectively. The same mea-
surements were 543 ± 149 mg/dl and 480 ± 158 mg/dl in homozygotes with normal
MPS. No significant difference was observed in total cholesterol and LDL levels in pa-
tients with or without myocardial ischemia (p = = 0.35). However mean total cholesterol
(252 ± 44 mg/dl) and LDL (181 ± 46 mg//dl) levels were significantly lower in dislipi-
demic patients than homozygote patients with or without myocardial ischemia
(p = 0.004 and p = 0.013, respectively).
Conclusions: We conclude that in patients with homozygote FHL, stress induced silent
myocardial ischemia can occur at a young age and that MPS should be performed early
as a screening test which can be used to guide patient management. In our study plas-
ma lipid levels were not diagnostic.
EVALUATION OF CARDIAC COMPLICATIONS WITH TC-99M TETROFOSMIN
GATED MYOCARDIAL PERFUSION SCINTIGRAPHY IN PATIENTS WITH
THALASSEMIA MAJOR
Meltem Tuncali1, Gonca Kara1, F. Gumruk2
1Nuclear Medicine, Hacettepe University Medical Faculty, Ankara, Turkey
2Pediatrics, Hacettepe University, Ankara, Turkey
Aim: Iron overload limits the life expectancy in thalassemic patients by causing cardiac tox-
icity. Iron also plays a catalytic role in the pathogenesis of atherosclerosis. The aim of this
study is to evaluate the role of Tc-99m Tetrofosmin gated myocardial perfusion study (GMPS)
to detect cardiac dysfunction in patients with thalassemia major.
Material and methods: 42 patients with homozygous beta-thalassemia were enrolled to the
study. Myocardial perfusion and wall motion were analysed in all patients aged 17 ± 5.28
and 34 age-matched controls with GMPS. Clinical data, liver function tests, hemoglobin,
ferritin, (low density lipoprotein) LDL and cholesterol levels, total transfusion number and
frequency were collected from the charts of the patients.
Results: 97.6% and 78.5% of patients had normal myocardial perfusion and wall motion
respectively. 9 of 42 thalassemic patients had abnormal left ventricular wall motion. Half of
those had septal hypokinesia. No significant correlation was found between total transfusion
number, serum ferritin levels, liver function test and left ventricular function (Table 1). Echocar-
diography revealed systolic dysfunction in 5 of 9 patients with wall motion abnormality. In all
patients LDL and cholesterol levels were within normal limits.
Conclusions: Regional wall motion abnormalities can be seen in patients with thalassemia
major. This early damage is frequently located in the septum and can be detected by GMPS.
Serum ferritin level, number of blood transfusions are inadequate as predictors of myocar-
dial dysfunction.
Table 1. Distribution of talassemic patients with and without wall motion abnormality
Parameter Wall motion Normal wall p
abnormality (n = 9) motion (n = 33)
Age (mean) 19.7 17.1 0.077
Sex, M/F 8/1 17/16 0.022
Ferritin < 2000/ ≥ 2000 ng/ml 5/4 17/16 1.00
Total transfusions < 200/ ≥ 200 2/7 14/19 0.44
ALT < 40/ ≥ 40 U/L 5/4 22/11 0.698
AST < 33/ ≥ 33U/L 5/4 20/13 1.00
ENDOCRINOLOGY
THE ROLE OF THYROID SCINTIGRAPHY IN HASHIMOTO THYROIDITIS:
COMPARISON WITH CLINICAL AND ULTRASONOGRAPHIC FINDINGS
Meltem Tuncali1, Eser Ergun1, Selcuk Dagdelen2, Tomris Erbas2
1Nuclear Medicine, Hacettepe University Medical Faculty, Ankara, Turkey
2Internal Medicine, Division of endocrinology, Hacettepe University Medical
Faculty, Ankara, Turkey
Aim: To evaluate various stages of Hashimoto thyroiditis (HT) with ultrasonograph-
ic and scintigraphic findings.
Material and methods: Eighty-six patients (14 M/72 F) with HT were included in the
study. The mean age of the patients was 39 yr (range, 14-73 yr). Thyroid scintigra-
phy was performed with Tc-99m pertechnetate and serum TSH, free T4, free T3,
thyroid peroxidase antibody (TPO Abs), TSH receptor antibody levels were obtained
in all patients. Ultrasonography was available in 41 patients (48%).
Results: Thyroid TPOAbs were elevated in 86 (100%) and TSH receptor antibodies
were elevated in 29 (33%) patients. USG revealed diffuse hyperplasia, multinodular
goiter and solitary nodule in 16 (39%), 21 (51%) and 4 (10%) patients respectively.
In Hashimoto disease, variable scintigraphic appearances were also seen. 9%, 35%,
42%, 5% and 9% of patients had normal scan, diffuse hyperplasia, multinodular
gland, solitary nodule, and suppressed glands respectively. Scintigraphic findings
were not correlated with TPOAb levels (p > 0.05). A significantly higher prevalence
of hyperthyroidism was observed in patients with diffuse goiter in comparison with
those with multinodular gland (63% vs. 22%). The relation between scan findings
and clinical presentation is shown on Table 1.
Conclusions: The scintigraphic findings in HT are highly variable and can mimic a
wide range of thyroid disorders. Our data suggest that diffuse radiopharmaceutical
uptake among hyperthyroid patients is suggestive of Graves disease or Hashitoxi-
cosis. In early stage Hashimoto disease TSH stimulation results in increased radio-
nuclide activity throughout the thyroid. Consequently, as more thyroid parenchyma
is replaced by fibrous tissue, a multinodular goiter develops.
Table 1. Correlation between scan and clinical findings
Clinical Multinodular Diffuse Suppressed Normal
presentation or solitary nodules hyperplasia gland
Euthyroid 16 (19%) 6 (7%) 1 (1%) 3 (3%)
Hyperthyroid 19 (22%) 21 (25%) 5 (6%) 5 (6%)
Hypothyroid 5 (6%) 3 (3%) 2 (2%) -
Total 40 (47%) 30 (35%) 8 (9%) 8 (9%)
NUCLEAR CARDIOLOGY (TC-99M-MIBI GSPECT) IN ACUTE
MYOCARDIAL INFARCTION
Anna Teresińska
National Institute of Cardiology, Warsaw, Poland (NIC)
Background: ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging
(2003), in Acute Coronary Syndromes (ACS), consider rest myocardial GSPECT as a procedure of
highest indication (class I) for: assessment of myocardial risk in suspected ACS (to identify high risk
pts with perfusion defects, who should be admitted), and for prognosis and assessment of therapy
after STEMI (myocardial infarction, MI, with ST elevation) and after NSTEMI or unstable angina. Rest
Tc-99m-MIBI myocardial perfusion imaging in the research use, takes adventage of specific char-
acteristics of the radiopharmaceutical: because of prompt mitochondrial binding of MIBI and its
minimal redistribution over time, imaging can be delayed for a few hours after the injection and still
provide accurate information about perfusion at the time of injection, regardless of coronary inter-
ventions between injection and imaging. Primary percutaneous coronary intervention (pPCI) is a
treatment of choice for acute STEMI. Standard pPCI is performed by stenting the infarct-related
artery (IRA). In patients with recognised STEMI, lack of perfusion in acute phase reflects the  myo-
cardium (myoc) at risk (RISK area); lack of MIBI accumulation in ischemic myoc is caused by
unpatent IRA, with mitochondrial membranes disrupted or not. Lack of perfusion after successful
pPCI reflects the myoc with final scar (SCAR area); lack of MIBI accumulation is caused by mito-
chondrial membranes disrupture. The aim of using serial rest Tc-99m-MIBI GSPECT imaging in AMI
can be the assessment of the tissue efficacy of pPCI and the evaluation of the time-evolution of
post-pPCI results. This is a tool dedicated to comparisons of different methods of pPCI in random-
ized studies.
The methodology used at NIC: After contrast angiography, before pPCI, pts are injected with 30
mCi of Tc-99m-MIBI. GSPECT-0 registration is performed 90-360 min later, after pPCI and patient's
stabilisation. GSPECT-I is performed 2-9 days later, GSPECT-II - after 6 mo. Perfusion is assessed
in 17 segments of LV by using 5-grade defect scale (0-normal, 4-lack of uptake); summary defect
score (SDS) is calculated. In GSPECT-0, RISK area is calculated as a number of segments with
uptake = 4 in VISUAL METHOD, and, alternatively, as the % of myoc with uptake <50% of maxi-
mum on a bull's-eye map in THRESHOLD METHOD. In GSPECT-I and -II, by the same methods, the
SCAR area is calculated; SALVAGE area = RISK-SCAR; salvage index SI = SALVAGE/RISK. EF,
EDV and ESV are calculated by QGS software from all the GSPECT studies. Patients with first
STEMI within 12 hrs from pain onset and TIMI flow < 3 are qualified.
Example 1. Early and late assessment of efficacy of standard pPCI after angiographically
successful pPCI.
Results: pPCI in pts with STEMI caused improved tissue perfusion in 84% of pts in early evaluation
and in 100% in 6-mo evaluation. The values of  SALVAGE area and SI improved early after pPCI and
further improved during next 6 mo. Temporary, early improvement in EF was observed; the values of
EDV and ESV did not change after pPCI.
Conclusion: After pPCI there are dynamic changes in left ventricular perfusion, salvage and func-
tion parameters.
Example 2. Comparison of efficacy of standard pPCI versus thrombectomy followed by stent-
ing (thrombe-pPCI). Randomized study.
Results: In GSPECT-I, SDS improvement, SALVAGE, SI, and EF improvement was not significantly
different between pPCI vs. thrombe-pPCI.
Conclusion: Coronary thrombectomy may not add benefits as adjunctive therapy to standard pPCI
in STEMI.
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SUCCESS RATE OF SINGLE DOSE RADIOIODINE-131 THERAPY
FOLLOWING FIXED OR CALCULATED DOSE APPROACH IN PATIENTS
WITH GRAVES' DISEASE
Adil Boz, Pinar Makinaci, Funda Aydin, Arzu Cengiz, Ümit Karayalçin,
Binnur Karayalçin
Departments of Nuclear Medicine and Endocrinology, Akdeniz University,
Faculty of Medicine, Antalya, Turkey
Aim: The aim of this study was to evaluate the effectiveness of single dose radioio-
dine-131 therapy and results of follow-up in patients with Graves’ disease.
Material and methods: Therapeutic effectiveness and follow-up results of 139 pa-
tients (31 male and 108 female, mean age: 45 ± 14 years) treated with radioiodine-
131 for Graves' disease between the years of 2000 and 2006 were evaluated retro-
spectively. Mean follow-up period after therapy were 18 ± 16 months. Radioiodine-
131 therapy was given orally using calculated dose (80–120 µCi/gr) or fixed dose
approaches in 17 and 122 patients, respectively. The criteria for successful therapy
was defined as euthyroidism or hypothyroidism after radioiodine therapy and, the
existence of hyperthyroidism six months after therapy was considered as unsuc-
cessful therapy. Twenty two patients were excluded from the study because of fail-
ure in follow-up. The success rates for both calculated and fixed dose groups were
determined.
Results: Mean doses were 8 ± 4 mCi and 10 ± 3 mCi in calculated and fixed doses
groups, respectively, and did not differ significantly (p > 0.05). Single dose suc-
cess rates were 38% in calculated dose group and 59% in fixed dose group. The
incidence of hypothyroidism after therapy was higher in fixed dose group com-
pared to calculated group (55% vs. 23%). There were no therapeutic complications
in the groups due to radioiodine.
Conclusions: Our results suggested that radioiodine-131 provides a safe and ef-
fective treatment for Graves' disease. Although the incidence of hypothyroidism
was higher, fixed dose approach was more effective and practical than calculated
dose approach.
PRIMARY HYPERPARATHYROIDISM WITH MULTIPLE BROWN TUMORS
— UNUSUAL CLINICAL PRESENTATION WITH RADIONUCLIDE
LOCALIZATION OF PARATHYROID ADENOMA — CASE REPORT
B.E. Chrapko1, A. Nocuń1, J. Malicka2, A. Nowakowski2, M. Sawicki3,
W. Cholewiński1
1Department of Nuclear Medicine 2Clinic of Endocrinology, Medical University
of Lublin, Poland
3Clinic of Thoracosurgery, Medical University of Lublin, Poland
We present a case of a 40 years old man, admitted to the hospital with acute symp-
toms of headache and diplopia with a history of nepholithiasis and peptic ulcer. He
also complained of polydipsia, and polyuria. Thirteen years ago he underwent subto-
tal thyroidectomy but his thyroid function was within normal limits. CT and MRI were
performed and revealed tumour of the sella turcica with infiltration of the sinus cavern-
osus. The patient underwent sublabial transseptal transsphenoidal tumour resectrion
with subsequent histological tissue assessment. It showed gigantocellular tumour and
a brown tumor.
Because the patient complained of miltifocal bone pain, bone scan with 99mTc-MDP
was performed. The images showed multiple foci of very intense tracer uptake, local-
ized mainly in the long bones. In addition, whole body MIBI scan was done.
Since the level of parathormon was 1900.0 pg/ml, the parathyroid scintigraphy with
99mTc-MIBI/ NaTcO4 was schedulted. The images were acquired with planar and
SPECT technique and intepreted with subtraction and clearence methods. There was
a very mild uptake medially to the right thyroid lobe, just above the isthmus, however
the scan was reported as inconclusive because not all scintigraphic criteria for posi-
tive scan were fulfilled . Patient underwent right lobe strumectomy with right parathy-
roidectomy. Because PTH levels remained very high, a repeat parathyroid scan was
performed with additional image fusion on CT images. The scan showed a very well
circumscribed area of high MIBI uptake within the right medial part of the neck, which
fused with a small focus on the CT scan. Repeat surgery was performed but this time
with intra-operative gamma probe after IV injection of 740MBq of 99mTc-MIBI.
The parathyroid adenoma was detected in the para-tracheal region and was successfully
removed. After surgical resection the PTH level returned to normal values (41 pg/ml).
The wide range of symptoms found in primary parathyroidism frequently may lead to
the misdiagnosis. In the above case, the advantages of radionuclide methods and
close collaboration of various medical disciplines managed to overcome prospected
difficulties.
TC-99M MDP BONE SCINTIGRAPHY IN DETECTION
OF DISTANT METASTASES FROM LUNG CANCER
L. Jaukovic, B. Ajdinovic, Z. Jankovic, S. Dugonjic
Institute of Nuclear Medicine, Military Medical Academy, Belgrade, Serbia
Background: Lung cancer is known to favour haematogenic dissemination raising
the possibility of distant metastases. The probability of a solitary  bone lesion  to be
malignant, is of considerable clinical interest.
Aim: To determine the incidence of abnormal bone scintigraphy (BS) scans and to
review the pattern of BS findings in lung cancer patients.
Material and methods: We retrospectively analyzed one hundred of patients
(78 males and 22 females) mean age of 63.3 years with diagnosis of lung cancer,
who underwent BS during the three  year’s period (2003–2005). Scintiscans were
classified as positive; negative and suspicious for bone metastases.
Results: The incidence of positive findings was 57%, negative findings 33% while
the image suspicious for bone metastases was obtained in 10% of patients. Out of
57 patients with bone metastases 51 scans showed multiple asymmetric foci of
increased tracer activity localized in ribs, spine, extremities, pelvis, sternum , scap-
ula and skull in 80%, 61%, 55%, 48%, 14%, 10% and 6 % of scans respectively. BS
revealed solitary metastases in 6 patients. Lesions were located in lower limbs in
three patients and in upper limb, pelvis and sternum in remaining three patients.
Conclusion: our results suggest that systematic inclusion of limbs in BS acquisition
should be necessary for accurate staging of lung cancer patients.
NORMAL ADRENAL UPTAKE OF THE SOMATOSTATIN ANALOGUE,
VISUALIZED IN SPECT EXAMINATION WITH 99MTC-EDDA/HYNIC-TOC
Anna Nocuń, Renata Gołębiewska, Witold Cholewiński, Beata Chrapko
Chair and Department of Nuclear Medicine, Skubiszewski Medical University of Lublin, Poland
Background: Interpretation of any radionuclide examination requires a knowledge of
the normal radiotracer distribution and its variants. As usually reported, the biodistri-
bution of the somatostatin analogues includes the uptake in the liver, gallbladder,
spleen, kidneys, colon, pituitary gland, salivary gland and breast (variable). Although
adrenal medulla expresses type 2 somatostatin receptors, only few papers describe
visualization of the normal adrenals in SPECT examination with radiolabeled soma-
tostatin analogues. In this paper we report how often the normal adrenals can be seen
in the scintigraphy performed with 99mTc-EDDA/HYNIC-TOC.
Material and methods: The studied group comprised 48 patients (27 females and 21
males), the mean age of the group was 58 years (range: 28-79 years). The patients
were diagnosed with neuroendocrine tumors (40 pts) or pulmonary carcinoma (8 pts)
and referred to the Department of Nuclear Medicine of Medical University of Lublin for
staging before a treatment by means of the somatostatin receptor scintigraphy. In all
the cases adrenal glands were reported as normal in CT examination, performed be-
fore the scintigraphy.
Imaging protocol: administered dose of 99mTc-EDDA/HYNIC-TOC ( 99mTc-Tektro-
tyd, POLATOM, Łódź, Poland) was 740 MBq. SPECT acquisition was performed two
hours after IV injection of the radiotracer, using a dual-head gamma-camera Varicam
Elscint. High-resolution collimators and a matrix of 128 × 128 pixels were applied.
One hundred and twenty projections were acquired, each of 30 s duration. Filtered
back projection with a Butterworth filter was used for reconstruction. Visual analysis of
the images was made by two specialists in nuclear medicine.
Results: Radiotracer activity in the area corresponding to the left adrenal gland ( "hot"
spot close to the upper pole of the left kidney) was observed in 15 (31.2%) patients
(7 females and 8 males). In 4 (8.3%) patients (1 female and 3 males) adrenal activity
was seen bilaterally (Table 1).
Conclusion: The normal distribution of 99mTc-EDDA/HYNIC-TOC, evaluated by
SPECT, in some adult patients may include adrenal uptake on one or both sides.
Table 1. Adrenal uptake of 99mTc-EDDA/HYNIC-TOC in 48 SPECT examinations
Uptake visible in SPECT Number of patients
Right adrenal only 0 (0%)
Left adrenal only 15 (31.2%)
Both adrenals 4 (8.3%)
Total 19 (39.5%)
68





COMPARISON OF SERUM THYROGLOBULIN, I-131 AND TC-99M
THYROID SCINTIGRAPHY, THYROID I-131 UPTAKE AND ULTRASONOGRAPHY
IN THE EVALUATION OF PATIENTS WITH THYROID CANCER AFTER
SURGERY
Meltem Tuncali, Ceren Kapulu
Hacettepe University, Ankara, Turkey
Aim: The extent of remnant thyroid tissue after surgery influences the outcome of
radioiodine ablation in patients with thyroid cancer. AIM: To evaluate the use of
neck ultrasonography (USG), Tc-99m thyroid scintigraphy (TS), iodine-I-131 scin-
tigraphy (IS), thyroid I-131 uptake (IU) and serum thyroglobulin (Tg) levels in the
evaluation residual thyroid remnants after surgery.
Material and methods: We prospectively studied 30 patients with a median age of
44 years (range, 21–68 years) with differentiated thyroid carcinoma treated with
total or near total thyroidectomy. Among them there were 22 patients with papillary
and 8 with follicular tumors. Patients with metastases and anti-Tg antibodies were
excluded. After optimal endogenous thyroid-stimulating hormone stimulation (> 30
mU/ml), 30 pairs of IS and TS and IU studies were performed one month after
thyroid surgery. Concomitant serum thyroglobulin levels were available for all pa-
tients. The presence or absence of thyroid tissue on scintigraphy was correlated
with USG and post-treatment whole body I-131 scintigraphy (WBS).
Results: None of our patients had extrathyroidal uptake on the post-treatment WBS.
Tg values 1 month after surgery were in the range of 0.2–21.0 ng/ml (median: 2.85
ng/ml). I-131 uptake in the thyroid bed varied between 0.1 to 8.7% (median: 1%).
Tg levels positively correlated with thyroid bed iodine uptake (r = 0.726, p < 0.0001).
IS and TS detected residual tissue in the neck in 21 (70%) and 15 patients (50%)
respectively. The agreement (kappa value) between IS and TS was 0,6%,
(p < 0. 0001). When IU values were > 1.5%, all patients had tracer uptake in the
thyroid bed both on IS and TS. IS and TS were able to show remnant tissue in 55%
and 25% of patients who had £ 1.5% IU, respectively. TS was found to be signifi-
cantly better (p < 0.005) than USG for the detection of remnant thyroid tissue.
Conclusions: For the postoperative evaluation of patients with well differentiated thy-
roid cancer without metastasis and anti-Tg antibodies, 1) IS is superior to TS for the
detection of residual thyroid tissue in patients with £ 1.5% iodine uptake, 2) detec-
table Tg levels correlate with tissue remnants and 3) postoperative measurement of
cervical I-131 uptake could be a guide in deciding the ablative dose of I-131.
OUR FIRST EXPERIENCES WITH  99MTC-HMPAO LABELLED WHITE CELL
(LEUCOSCINT) IN EVALUATION PATIENTS WITH INFLAMMATORY
BOWEL DISEASES
S. Planic1, S. Ilic2, A.Simic1, R. Spaic1
1Center for Nuclear Medicine- Medica Nucleare Belgrade, Serbia
2Center for Nuclear Medicine-Nis, Serbia
The aim of the study was to verify the effectiveness of lyophilized 99mTc-HMPAO
labeled white cells in the detection of inflammatory foci in patients with bowel dis-
eases.
A total number of 9 patients with clinical suspicion of bowel inflammation were in-
vestigated. Additional data were provided using clinical finding, ultrasonography,
computer tomography and magnetic resonance imaging, colonoscopy and labo-
ratory analysis for confirmation of bowel inflammation. The white cells were recon-
stituted with 99mTc-HMPAO (Leuco-Scint, Medi-Radiopharma, Hungary) expect-
ing at least 80% of lipophilic label complexes. After reconstitution 99mTc-HMPAO
labelled white cells were intravenously reinjected in dose 55–740 MBq. Serial imag-
ing at 5 min, 1, 2 and 3 hours were performed in whole body static planar modality
(anterior and posterior view abdomen and pelvis). When needed, additional scinti-
grams were acquired after and 24 h. In 4 patients with equivocal findings on planar
scintigraphy, emission computed tomography was performed. There were positive
findings in all evaluated patients with bowel inflammation (four due to Crohns dis-
ease, three to ulcerative colitis and two to inflammatory enterocolitis). Increased
white cells accumulation was found to be located in different parts of bowel. In 5
patients (55%), was registered more than one focal site of intensive white cells dis-
tribution. The rate of appearance of positive uptake was concordant with clinically
manifested intensity of bowel inflammation. According to our results scintigraphy
with 99mTc-HMPAO labelled white cells is a useful method for detection, assessment
of exact localization and rate of intensity of inflammatory foci in bowel diseases.
THERAPY
RADIOIMMUNOTHERAPY IN FOLLICULAR LYMPHOMAS:
A RETROSPECTIVE ANALYSIS OF PLRG EXPERIENCE
Wojciech Jurczak1, Alicja Hubalewska-Dydejczyk2, Agnieszka Giza1,
Anna Sowa-Staszczak2, Tomasz Wróbel3, Grzegorz Mazur3, Piotr Boguradzki4,
Wanda Knopińska-Posłuszny5, Bohdan Huszno2, Aleksander B. Skotnicki1
1Department of Hematology, Collegium Medicum, Jagiellonian University, Kraków
2Nuclear Medicine Unit; Department of Endocrinology; Collegium Medicum,
Jagiellonian University, Kraków
3Department of Hematology, Blood Neoplasms and Bone Marrow
Transplantation, Wroclaw Medical University
4Department of Hematology, Oncology and Internal Medicine, Academy
of Medicine, Warsaw
5Department of Hematology, Academy of Medicine, Gdańsk
The paper summarizes the result of 21 follicular lymphoma patients subjected to
radioimmunotherapy in PLRG centers. Ibritumomab (Zevalin) is the only radioim-
monoconjugate currently available in Europe registered for treatment of follicular
lymphoma relapsing or refractory after Rituximab. It combines the specificity of an
anti CD20 monoclonal antibody with the power of beta emitting 90Y, being particu-
larly efficient in a fibrosed, poorly vascularised lymph nodes.
All 21 patients were heavily pretreated, after failing 2–6 lines of previous therapy. In
the whole group median event free survival exceeded 15 month, and overall survival
was not yet reached at 45 months of follow-up. Subgroup analysis and literature
review are included, to identify patients which could merit most of RIT.
Key words: radioimmunotherapy, Zevalin, Ibritumomab, follicular lymphoma
TREATMENT OF SMALL AND MEDIUM JOINTS BY MEANS
OF RADIOSYNOVIORTHESIS
R. Kašpárek1, O. Kraft2, A. Stepien3
1Orthopaedic Department, University Hospital, Ostrava-Poruba, Czech Republic
2Department of Nuclear Medicine, University Hospital, Ostrava-Poruba,
Czech Republic
3Department of Nuclear Medicine, 5th Clinical Military Hospital, Cracow, Poland
Aim: To familiarize with the indications, doing, treatment results of the radiosynovior-
thesis (RSO) of medium and small joints in patients with rheumatoid arthritis (RA).
Material and methods: The RSO is intraarticular treatment with beta emitters. For
correct indication one should accomplish before RSO clinical examination (pres-
ence of a pain, swelling, joint motion), ultrasonography (US) (filling and synovial
reaction), X-ray (Larsen's classification); it is suitable three-phase bone scintigra-
phy. Treatment effect is possible to expect only when synovitis is proved by these
procedures. Control clinical and US examinations are done after 6 and 12 months.
Orthopaedist applies rhenium sulfide to medium joints (70–110 MBq) and erbium
citrate (20–40 MBq) to small joints under US control in sterile conditions after appli-
cation 1% Mesocain, i.a. After RSO the joint is immobilized for 2–3 days.
Results: From VI/2002 to IX/2005 we have done 45 RSO of medium joints in 36
patients — 4 elbows, 11 ATC, 5 shoulders, 25 RC and RSO of 45 small joints in 17
patients — MCP and PIP of hands. Evaluation of treatment effect after RSO of me-
dium joints: by patients (effect on pain and formation of fluid) and clinical evaluation
(by orthopaedist): shoulders: in 100% reduction of pain and swelling, in 60% im-
provement of motion, in 100% reduction of synovial reaction; elbow: in 100% reduc-
tion of pain, in 75% reduction of swelling, in 75% identical motion, in 50% US im-
provement, 1 ¥ post-radiation synovitis treated conservatively; RC: in 68% reduc-
tion of pain and swelling, in 28% improvement of motion, in 64% US improvement,
1 ¥ ¥ re-RSO after one year; TC: in 72% reduction of pain, in 72% identical swelling
and motion, in 18% US improvement, in 2 pts repeated RSO after one year. Small
joints: in 72% reduction of pain, in 56% reduction of swelling, in 11% motion im-
provement, in 50% US improvement, 1 ¥ re-RSO of MCP after one year.
Conclusions: RSO of medium and small joints reduces volume and activity of syn-
ovial tissue and volume of produced fluid. It decreases intra-cavitary pressure, pain
and secondary destruction of articular structures and postpones surgical invasive
therapy. It reduces possible risks from surgical therapy and costs of further treat-
ment. RSO advantages: semi-invasive method with good effect. It can be repeated
in sever part of treatment series. It is possible to use RSO as separate therapeutic
intervention or as supplement of surgical therapy.







MAGNETIC IRON OXIDE LABELLED WITH 54MN AS A POSSIBLE DRUG CARRIER
Małgorzata Kłos, Mirosław Bartyzel, Barbara Petelenz
Department of Nuclear Physical Chemistry, Institute of Nuclear Physics, Cracow, Poland
Aim: Magnetic nano- and microparticles of iron(II,III) oxide Fe3O4 are interesting as possible drug
carriers whose migration to target tissues can be enhanced by external magnetic fields. The isotope
54Mn (312.3 d, 100% EC, gamma 834.848 keV 99.976%), a convenient single photon calibration
source, is known from preclinical research on the function and movement in the brain [1–3]. Manga-
nese as Mn+2, Mn+3 and Mn+4 ions is involved in the metabolism of proteins, lipids and carbohy-
drates. Magnetic field-enhanced in vivo transport of [54Mn]Fe3O4 can give more information about
metabolism of both metals in target sites. The aim of this work was synthesis of Fe3O4 and its
labelling with manganese 54Mn whose chemical properties are close to those of iron.
Material and methods: The label 54Mn was produced in the 51V(a,n)54Mn reaction by alpha-particle
activation of vanadium(V) oxide V2O5 of natural isotopic abundance (99,75% 
51V). 54Mn was separat-
ed from HCl solution on Dowex-50x8 resin in the presence of an internal tracer 48V, produced in the
same cyclotron via natTi(p,xn)48V reaction. The micro-component 54Mn was eluted from the column
with 3 M HCl, and the macro-component vanadium with 0.1M HCl/ethanol/H2O2 mixture. Magnetic
suspension of Fe3O4 was produced in the 6Fe
3+ + SO3
2– + 18NH4OH Æ 2Fe3O4Ø + + SO4
2– +
+ 18NH4
+ + 9H2O reaction [4] from freshly prepared reagents under heavy stirring and bubbling
with Argonne gas at 70∞C. The black precipitate was centrifuged and washed with water and with
water-ethanol mixture. The labelled Fe3O4 was produced in the same way by co-precipitation with
54Mn added as 54MnCl2. Radioactive samples were identified by gamma-ray spectrometry, using a
35cm3 HPGe co-axial detector coupled with a multichannel analyser.
Results: The carrier-free 54Mn was of 99.9% radionuclide purity. The black precipitate of Fe3O4
exhibited well expressed magnetic properties. Labelling with 54Mn was quantitative (Figure 1). Sta-
bility of the precipitate in vitro is still to be checked.
Conclusions: Although the long half-life of 54Mn rules it out as a radiopharmaceutical, its excellent
detection properties can help in observation of labelled Fe3O4 in pre-clinical research.
Figure 1. Gamma spectrum of the filtrate
(bottom) and of the Fe3O4 sediment (top, shifted
by n = 10).
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SYSTEM FOR COMPLEX MATHEMATICAL ANALYSIS AND CLINICAL
EVALUATION OF FUNCTIONAL SCINTIGRAPHY ON PC
V. Ullmann, O. Kraft, A. Slanina
Department of Nuclear Medicine, University Hospital, Ostrava-Poruba,
Czech Republic
The software for the complex mathematical analyses of scintigraphic examinations
performed on the standard PC computers, has been developed in the Nuclear
Medicine Department at University Hospital in Ostrava. Besides conventional pro-
cedures for the individual (manual) processing of pictures and curves, our software
contains a lot of complex programmes for the mathematical analyses of the dynam-
ic scintigraphic examinations (e.g. for gated ventriculographic studies, the first pass
radiocardiographic studies, dynamic kidneys and liver studies, myocardial perfu-
sion studies etc.). A lot of original methods and procedures have been applied in
these programmes. They give us quick, automaticl and exact evaluation with the
maximal complexity. Operating these programmes is very easy, time and labour
saving for a user. The output of each programme is an entire protocol containing
information about patient, scintigraphic and parametric pictures of all important
examination phases, time-activity curves of ROI´s, numerical values of quantitative
parameters as well as the verbal evaluation of whole examination with a short con-
clusion. It is very easy to use this system on any PC by means of Windows 95-2000
or higher and it is able to evaluate studies taken from various scintillation cameras.
www.AstroNuklFyzika.cz
INTER AND INTRA VARIABILITY OF TC-99M DMSA RENAL SCINTIGRAPHY
IN CHILDREN: IMPACT OF OBLIQUE VIEWS
Meltem Tuncali1, Pinar Kiratli1, Erdem Karabulut2
1Nuclear Medicine, Hacettepe University Medical Faculty, Ankara, Turkey
2Biostatistics, Hacettepe University Medical Faculty, Ankara, Turkey
Aim: Technetium-99m-dimercaptosuccinic acid (DMSA) renal scintigraphy is fre-
quently used to assess the presence and severity of kidney damage. This work was
undertaken to evaluate the level of inter and intra-observer variability of Tc-99m
DMSA scintigraphy and to identify the impact of posterior oblique views on scan
interpretation in the pediatric population.
Material and methods: A total of 100 DMSA renal scans (197 kidneys) were evalu-
ated. Two nuclear medicine physicians independently interpreted the images four
times; twice only from the posterior projection views and twice from the posterior
and posterior oblique views. For each kidney, the observers had to choose be-
tween the following results: normal, abnormal and indeterminate. The indices of
variability used were the percentage of agreement, kappa statistic and marginal
homogeneity test.
Results: Disagreement of DMSA scan interpretation was present in 18% of kidneys
within observers and in 21% cases between observers when only posterior images
were used. Oblique views changed the interpretation in 14% and 11.5% kidneys for
the first and second observer respectively. The intra- and inter-observer reproduc-
ibility (kappa values) varied between 0.683 and 0.708 for intra- , between 0.609 and
0.671 for inter-observer variability when only posterior views were used. With the
addition of oblique views the kappa values improved slightly (0.725–0.812 and 0.768–
–0.732 respectively).
Conclusions: Oblique views were found useful in approximately 13% of kidneys
and had effect on inter- and intra-observer variability. Our results suggest that they
should be used routinely in children with a clinical suspicion of UTI to obtain reliable
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EXPERIENCE WITH MPI WITH MYOVIEW IN NUCLEAR MEDICINE
DEPARTMENT OF UNIVERSITY HOSPITAL OSTRAVA, CZECH REPUBLIC
Otakar Kraft, Vojtech Ullmann, Jan Pekárek
University Hospital Ostrava, Czech Republic
From 1973 (opening of our department of nuclear medicine) we performed myocar-
dial perfusion planar scintigraphy using 201Tl chloride. From 1993 we have used SPECT
with 99mTc tetrofosmin (Myoview GE Healthcare) and 201Tl chloride, last 11 years SPECT
only with 99mTc Myoview — non-gated, since April 2003 gated SPECT. 80% of stress
studies used bicycle ergometry, 20% pharmacological stress — dipyridamole, rarely
dobutamine.
Our equipment: from 1993 and 1994 to 2006 was:  two single headed SPECT camer-
as DIACAM Siemens with HR collimator, from 2003 double headed SPECT camera
E.CAM Siemens with LEHR collimator, from 2007 double headed SPECT camera Sym-
bia S Siemens with LEHR collimator. Additional equipments: 12-point ECG, ergome-
ter, defibrillator, laryngoscope, ambuvac, pharmaceuticals for resuscitation. Stress
studies are performed only at the presence NM specialist (rarely cardiologist — mainly
dobutamine stress) trained in stress test and specialised secondary educated staff.
Main indications for MPI are:
— myocardial ischemia — detection, localization, relevancy;
— evaluation of the stenosis detected by coronarography, risk stratification;
— myocardial viability in patients with left ventricle dysfunction in revascularization
planning;
— evaluation of revascularization effect (PTCA or bypass-CABG) in patients with symp-
tom recurrence or with positive or nondiagnostic stress EKG;
— acute coronary syndrome.
Relative contra-indications for MPI are: pregnancy (tests are done only in vital indica-
tion at limited dose) and lactation.
Applicated activity of radiopharmaceutical 99mTc tetrofosmin (Myoview) is 600–1000 MBq.
When we combine stress and rest studies (pathological finding in stress study), we
use only two-day protocol.
Patient preparation: It is prefered to have patients empty-bellied (except in diabetic
patients), 12 hours before study to drink or eat food and drinks caffeine-free (possibil-
ity of pharmacogical stress), to withdraw beta blockers for 48 hours. In rest studies for
detection of viability a nitroglycerine is administered (except in patients with hypoten-
sion) 3–5 minutes prior Myoview application. Intravenous cannula is obligatory.
Bicycle ergometry: monitoring of ECG and blood pressure, starting at 25–50 W and
gradually individually increasing. Stress should not be shorter than 4 min. with respect
to angina pectoris, dyspnoea or strong EKG differences, arytmy etc. RF is applied at
the top of stress at about 85% of max. aerobic capacity (75% in patients after IM or
revascularization) and test continues another 1.5 min.
Then myocardial perfusion scintigraphy is done. Using 99mTc Myoview acquisition starts
15–30 min. after RF application.
Pharmacological stress with dipyridamole: monitoring of ECG and blood pressure,
application dose — i.v. infusion 0.56 mg/kg of Curantyl during 4 min. Physical stress
during the test is suitable — elimination of side effects, reduction of  splanchian vascu-
larization. 100–300 mg aminophylline i.v. blockades effect of dipyridamole in case of
troubles after test.
Acquisition: gated-SPECT, supine position is basic. In patiens with attenuation of pos-
terior (mainly in obese pts) or anterior (in some women) wall, the prone position is
appended.
For processing we use programme 4DMSPECT.
Conclusions: Scintigrams quality using Myoview is excellent. With radiopharmaceuti-
cal Myoview the problems with activity in liver or stomach or bowels are only rare.
These cases are easily solvable — to repeat study after drinking some liquids or eat-
ing some food or chocolate. Myoview preparation is easy and quick. It is not neces-
sary to boil it.
It is possible to use up to 12 GBq in volume 8 ml from one vial and to examine great
number of patients. It is economically very advantageous. Our satisfaction with
Myoview is great.
Figure 1.  Numbers of MPI
stress and rest studies in our
department.
Figure 2. Temporary stress ischaemia in posterolateral segment of left ventricle in 65
years old man with angina pectoris syndrome.
SIGNIFICANCE, DETECTION AND BIOPSY OF SENTINEL LYMPH NODES
IN SOME TYPES OF MALIGNANT TUMOURS
Otakar Kraft, Jirina Heroková, Romuald Curík, Ladislav Petráš, Otakar Kubala,
Jirí Prokop, Josef Kopecký, Libor Ševcík, Yvetta Vantuchová
University Hospital Ostrava, Czech Republic
Background: Sentinel lymph node biopsy has revolutionized the surgical management of primary
malignant melanoma and breast cancer.
The authors conducted a retrospective review of 530 patients treated  for malignant melanomas,
505 pts for breast cancers, 85 for cervical cancers, 19 for vulvar cancers, 1 for vaginal cancer, 16 for
prostate cancers, 2 for penile cancers, 3 for oral cancers  with lymphoscintigraphy, patent blue dye
and gamma probe guided sentinel lymph node biopsy since 2000.
Methods and results: In all patients with various types of tumours the operation was performed with
preoperative technetium 99mTc lymphoscintigraphy (with three types of radiocolloids: Nanocis Cis
bio International Gif-sur-Yvette Cedex, France, Nanocoll Nycomed Amersham Sorin, Saluggia, Italy
and SentiScint FJC National Research Institute for Radiobiology and Radiohygiene, Budapest, Hun-
gary), patent blue dye and gamma probe guided sentinel lymph node biopsy. Sentinel lymph nodes
were examined by means of histological and immunohistochemical examinations.
Melanoma patients: 530 patients (249 male and 281 female patients, age from 10 to 84 years,
average age 56 yrs) were identified. Melanoma thickness according to Breslow in the group of our
patients was in a wide range from 0.18 to 14 mm, the tumour invasion across cutaneous zones
(Clark’s levels) I–V. The primary melanoma sites were the scalp (n = 14) , the neck (n = 6) , the
truncal melanomas (n = 255), the upper extremity (n = 118), the lower extremity (n = 132), the
vagina and vulva (n = 5). Lymph node basins (one, two or even three in every patient)  were identi-
fied in the axilla, in the inguinal region, less common locations - the popliteal, truncal, neck, sub-
mandibular, preauricular and supraclavicular regions. The lymph nodes were affected by metastas-
es in 80 patients (in 16.8% from 476 patients in whom the SLN was removed).
A standard regional dissection of lymph nodes was subsequently carried out in these patients with
SLN metastasis.
Breast cancers patients: To prove sentinel lymph nodes, we examined 501 women and 4 men with
diagnosis of breast cancer (aged 58.5 years on average; tumour size from T1a to T2, in 6 pts T3) in
one- or two-day protocol. Lymph node metastasis was detected in 167 patients, i.e. in 33.1% of the
operated patients. Out of these 167 patients with metastasis-affected node there were 7 patients
with affected axillary lymph node without any affection of the sentinel lymph node, which means that
skip metastasis (false negativity of SLN) was proved in 4.2% (7 in 167). In some patients SLN biopsy
was combined with axillary lymph node dissection (ALND) and ALND was performed in all patients
with SLN metastasis.
Patients with other types of tumours: We examined 2 pts with penile cancer (one of them had SLN
metastasis), 16 pts with prostate cancer (6 pts with SLN metastasis), 3 pts with oral cancer (two with
SLN metastasis), 19 pts with vulvar cancer (9 with SLN metastasis), 1 with vaginal cancer. 127 pts
with cervical cancer were examined in one- or two-day protocol (after exclusion 45 pts with stage
FIGO III we included 85 pts — 3 pts had SLN metastasis). After SLN biopsy all women underwent
lymph node dissection and hysterectomy according Wertheim-Meigs with radicalism PIVER II, III).
Conclusions: In melanoma and breast cancer patients sentinel lymph node biopsy is highly reliable
in experienced hands. This study shows the importance of lymphoscintigraphy, the gamma probe
and patent blue dye in all lymph node basins but mainly in the axilla and unusual basins.
Completion therapeutic lymphadenectomy is recommended after positive biopsy because it is dif-
ficult to predict the presence of positive nonsentinel nodes. The method reduced distinctively a
number of elective lymphadenectomies much-favoured some years ago.
In all types of tumours the success of localization of SLN was directly related to simultaneous use of
scintigraphy, the surgical probe and patent blue dye.
Sentinel lymph node biopsy is very useful in surgical management of primary malignant melanoma
and breast cancer. In other types of tumours the role of sentinel lymph node biopsy is also signifi-
cant and feasible but its results are not as unequivocal and optimistic as in breast cancer and
malignant melanoma, and it is still experimental. For scintigraphy and intraoperative gamma probe
the differencies among three radiopharmaceuticals were not great, however in malignant melano-
ma patients Nanocoll detected more SLNs on average. It is possible safely avoid axillary dissection
in breast cancer in tumours of the size up to 1 centimetre (T1a and T1b) with negative SLN. The SLN
identification rate in malignant melanoma and breast cancer and the SLN false-negative rate in
breast cancer are comparable with other studies.
Figure 1. SLNs in both axilla in 72 yrs old
woman with malignant melanoma of the
back.
Figure 2. Several SLNs in 60 yrs old wom-
an with cancer of the left breast.
Figure 3. Several SLNs in 66 yrs old man
with prostate cancer.
Figure 4. Two SLNs in 63 yrs old woman with cervical cancer.
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